1
0This research highlights the therapeutic potential of RAS(ON) multi-selective inhibitors for treating cholangiocarcinoma (CCA), a lethal bile duct cancer often driven by KRAS mutations. Using various preclinical models and patient data, the authors demonstrate that these inhibitors effectively block the active state of RAS proteins to trigger tumor regression and improved survival. The findings identify oncogenic flux—specifically through MYC expression and KRAS amplification—as a primary driver of drug resistance. Furthermore, the study reveals that combining these inhibitors with standard chemotherapy significantly enhances anticancer activity compared to single-agent treatments. This work establishes a translational roadmap for utilizing RAS-GTP inhibition to redefine the clinical management of this difficult-to-treat malignancy.
References:
Entrialgo-Cadierno R, Morali K, Feliu I, et al. Anticancer activity of RAS-GTP inhibition in cholangiocarcinoma[J]. Cancer Cell, 2026.
